AR072041A1 - Piridil-n-(1,3,4) -tiadiazol-2-il-benceno sulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos - Google Patents
Piridil-n-(1,3,4) -tiadiazol-2-il-benceno sulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticosInfo
- Publication number
- AR072041A1 AR072041A1 ARP080105715A ARP080105715A AR072041A1 AR 072041 A1 AR072041 A1 AR 072041A1 AR P080105715 A ARP080105715 A AR P080105715A AR P080105715 A ARP080105715 A AR P080105715A AR 072041 A1 AR072041 A1 AR 072041A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkylene
- alkyl
- cycloalkyl
- trisubstituted
- mono
- Prior art date
Links
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 15
- 125000002947 alkylene group Chemical group 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000004366 heterocycloalkenyl group Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- 108010015181 PPAR delta Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010012305 Demyelination Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 108010016731 PPAR gamma Proteins 0.000 abstract 1
- 102000000536 PPAR gamma Human genes 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- -1 cyclic N- [1,3,4] -thiadiazol-2-yl-benzenesulfonamides Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
Abstract
Se refiere a N-[1,3,4]-tiadiazol-2-il-bencensulfonamidas c¡clicas y a sus sales fisiologicamente aceptables y derivados fisiologicamente funcionales que muestran actividad agonista de PPARdelta o PPARdelta y PPARgamma. Los compuestos son adecuados para el tratamiento y/o prevencion de trastornos de metabolismo de cidos grasos y trastornos de utilizacion de la glucosa, as¡ como de trastornos en los que est implicada la resistencia a la insulina y la desmielinizacion y otros trastornos neurodegenerativos del sistema nervioso central y periferico. Reivindicacion 1: Compuestos de la formula (1) donde R1 es alquilo C1-6, alquileno C0-6-cicloalquilo C3-6, alquileno C0-6-O-alquilo C1-6, alquileno C0-6-O-cicloalquilo C3-6, alquileno C0-6-arilo C6-14, alquileno C0-6-heteroarilo C5-15, en donde alquilo, alquileno, arilo, heteroarilo y cicloalquilo pueden estar no sustituidos o pueden estar mono-, di- o trisustituidos con F, CI, Br, alquilo C1-6, O-alquilo C1-6, CF3, OCF3, CN, CO-alquilo C1-6, COO-alquilo C1-6, CON-alquileno C0-6-H-alquileno C0-6-H, S(O)m-alquilo C1-6; R2, R3 son, de modo independiente, H, halogeno, alquilo C1-6, alquileno C0-4-O-alquileno C0-4-H, CN, COO-alquilo C1-6, CON-alquileno C0-6-H-alquileno C0-6-H, S(O)m-alquilo C1-6, en donde alquilo y alquileno son no sustituidos o mono-, di- o trisustituidos con F; R4, R5, R6 y R7 son, de modo independiente, H, alquilo C1-6, alquileno C0-6-cicloalquilo C3-6, alquileno C0-6-arilo C6-14, alquileno C0-6-heteroarilo C5-15, alquileno C0-6-heterocicloalquilo C3-15, alquileno C0-6-heterocicloalquenilo C3-15, en donde alquilo, alquileno y cicloalquilo no son sustituidos o son mono-, di- o trisustituidos con halogeno, alquilo C1-6, alquileno C0-6-O-alquileno C0-6-H, CF3, OCF3, CN, CO-alquilo C1-6, COO-alquilo C1-6, CON-alquileno C0-6- H-alquileno C0-6-H, S(O)m-alquilo C1-6, y en donde arilo, cicloalquilo, heterocicloalquilo, heterocicloalquenilo y heteroarilo no son sustituidos o son mono-, di- o trisustituidos con halogeno, CF3, alquilo C1-6 y alquileno C0-4-O-alquileno C0-4-H y en donde al menos un par de R4 y R5, R6 y R7, R5 y R6 junto con los tomos de C a los que est n conectados, o R6 junto con el tomo de C orto del anillo arom tico, forman un cicloalquilo C3-9, un heterocicloalquilo C3-9 o un heterocicloalquenilo C3-9, en donde cicloalquilo, heterocicloalquilo y heterocicloalquenilo no son sustituidos o son mono-, di- o trisustituidos con halogeno, CF3, alquilo C1-6 y alquileno C0-4-alquileno C0-4-H; m es 0, 1, 2; en todas sus formas estereoisomericas, formas enantiomericas y mezclas en cualquier relacion, y sus sales fisiologicamente aceptables y formas tautomericas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07291626 | 2007-12-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072041A1 true AR072041A1 (es) | 2010-08-04 |
Family
ID=39356534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105715A AR072041A1 (es) | 2007-12-26 | 2008-12-23 | Piridil-n-(1,3,4) -tiadiazol-2-il-benceno sulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8344004B2 (es) |
| EP (1) | EP2240474B1 (es) |
| JP (1) | JP2011507914A (es) |
| KR (1) | KR20100101165A (es) |
| CN (1) | CN101910162A (es) |
| AR (1) | AR072041A1 (es) |
| AT (1) | ATE549332T1 (es) |
| AU (1) | AU2008340756A1 (es) |
| BR (1) | BRPI0821915A2 (es) |
| CA (1) | CA2710441A1 (es) |
| IL (1) | IL206531A0 (es) |
| MX (1) | MX2010006647A (es) |
| TW (1) | TW200940536A (es) |
| WO (1) | WO2009080223A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007310897A1 (en) * | 2006-10-25 | 2008-05-02 | Neurosearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CA2798330A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| TWI754702B (zh) * | 2016-12-28 | 2022-02-11 | 德商Ｕｃｂ製藥有限公司 | （氮雜）吲哚－和苯並呋喃－３－磺醯胺類 |
| US20200206309A1 (en) * | 2017-07-27 | 2020-07-02 | The Mclean Hospital Corporation | METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF NURR1- AND PPARy-MEDIATED CONDITIONS |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| AU2020296361A1 (en) | 2019-06-18 | 2022-01-06 | Ctxt Pty Ltd | Benzisoxazole sulfonamide derivatives |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3522638A1 (de) * | 1985-06-25 | 1987-01-08 | Diamalt Ag | Neue somatostatin-derivate |
| WO1997040017A2 (en) | 1996-04-19 | 1997-10-30 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| MXPA06000118A (es) | 2003-07-08 | 2006-04-27 | Novartis Ag | Compuestos de bencensulfonamino y composiciones farmaceuticas que contienen estos compuestos. |
| CN101282952A (zh) | 2005-10-06 | 2008-10-08 | 塞诺菲-安万特股份有限公司 | 环状n-[1,3,4]-噻二唑-2-基-苯磺酰胺，其制备方法以及其作为药物的应用 |
| CN101277940A (zh) | 2005-10-06 | 2008-10-01 | 塞诺菲-安万特股份有限公司 | 4-氧基-n-[1,3,4]-噻二唑-2-基-苯磺酰胺、它们的制备方法及它们作为药物的用途 |
-
2008
- 2008-12-12 AU AU2008340756A patent/AU2008340756A1/en not_active Abandoned
- 2008-12-12 CN CN2008801232634A patent/CN101910162A/zh active Pending
- 2008-12-12 EP EP08864630A patent/EP2240474B1/en not_active Not-in-force
- 2008-12-12 BR BRPI0821915-0A patent/BRPI0821915A2/pt not_active IP Right Cessation
- 2008-12-12 AT AT08864630T patent/ATE549332T1/de active
- 2008-12-12 MX MX2010006647A patent/MX2010006647A/es not_active Application Discontinuation
- 2008-12-12 CA CA2710441A patent/CA2710441A1/en not_active Abandoned
- 2008-12-12 WO PCT/EP2008/010559 patent/WO2009080223A1/en not_active Ceased
- 2008-12-12 JP JP2010540045A patent/JP2011507914A/ja not_active Withdrawn
- 2008-12-12 KR KR1020107016753A patent/KR20100101165A/ko not_active Withdrawn
- 2008-12-23 AR ARP080105715A patent/AR072041A1/es unknown
- 2008-12-24 TW TW097150346A patent/TW200940536A/zh unknown
-
2010
- 2010-06-09 US US12/796,886 patent/US8344004B2/en not_active Expired - Fee Related
- 2010-06-21 IL IL206531A patent/IL206531A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110224263A1 (en) | 2011-09-15 |
| EP2240474A1 (en) | 2010-10-20 |
| EP2240474B1 (en) | 2012-03-14 |
| AU2008340756A1 (en) | 2009-07-02 |
| WO2009080223A1 (en) | 2009-07-02 |
| JP2011507914A (ja) | 2011-03-10 |
| MX2010006647A (es) | 2010-08-17 |
| ATE549332T1 (de) | 2012-03-15 |
| CA2710441A1 (en) | 2009-07-02 |
| CN101910162A (zh) | 2010-12-08 |
| US8344004B2 (en) | 2013-01-01 |
| TW200940536A (en) | 2009-10-01 |
| BRPI0821915A2 (pt) | 2015-06-16 |
| KR20100101165A (ko) | 2010-09-16 |
| IL206531A0 (en) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072041A1 (es) | Piridil-n-(1,3,4) -tiadiazol-2-il-benceno sulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos | |
| AR072013A1 (es) | Sulfonamidas n-heterociclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas | |
| AR064299A1 (es) | Derivados de sulfonil-fenil-2h- [1,2,4] oxadiazol-5-ona procesos para su preparacion y su uso como agentes farmaceuticos | |
| ECSP088323A (es) | Derivados de fenil-[1,2,4]-oxadiazol-5-ona con grupo fenilo, procedimientos para su preparación y su uso como productos farmacéuticos | |
| UY31873A (es) | Pirrolidin sulfonamidas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparación y su uso como sustancias farmacéuticas | |
| AR072014A1 (es) | Sulfonamidas con grupo de cabeza de heterociclo y oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas | |
| DOP2019000104A (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer | |
| UY34239A (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| PE20090049A1 (es) | Derivados de piridopirimidina como moduladores de la actividad de pde 4 | |
| EA201592146A1 (ru) | Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам | |
| PE20180929A1 (es) | Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5 | |
| AR077346A1 (es) | Compuestos heterociclicos como inhibidores de janus quinasa | |
| NI201300072A (es) | Derivados de heteroarilo como moduladores nachr alfa 7 | |
| AR072819A1 (es) | Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras | |
| ECSP066669A (es) | Indoles, 1h-indazoles, 1,2-benzisoxazoles, y 1,2-benzisotiazoles, y preparación y usos de los mismos | |
| MX364527B (es) | Derivados de triazolona de piridinilo y piridinilo fusionado. | |
| AR072820A1 (es) | Derivados de imidazo[1,2-a]pirimidina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras | |
| ECSP16090804A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| CL2015000559A1 (es) | Compuestos derivados de 2-oxo-2,3-dihidro-indoles; su proceso de obtencion; composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de trastornos del snc que son sintomas positivos o negativos de la esquizofrenia, el abuso de sustancias, la adiccion a alcohol y las drogas, enfermedad de alzheimer, enfermedad de parkinson, entre otras. | |
| CO2019005090A2 (es) | Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartílagos | |
| NI201600161A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| DOP2006000203A (es) | Derivados de fenil-1,2,4-oxadiazolona, procesos para su preparación y su uso como compuestos farmacéuticos | |
| PE20180316A1 (es) | Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda | |
| BR112015022290A2 (pt) | derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120 | |
| PE20190778A1 (es) | Derivados de eter ciclico de pirazolo[1,5-a]pirimidin-3-carboxiamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |